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Context: Type 2 diabetes is associatedwith a higher risk formajor osteoporotic fracture (MOF) and
hip fracture thanpredictedby theWorldHealthOrganization fracture risk assessment (FRAX) tool.
Objective: The objective of the study was to examine the impact of diabetes duration on fracture
risk.
Methods: Using a clinical dual-energy x-ray absorptiometry registry linked with the Manitoba
administrative databases, we identified all women age 40 years or older with 10 or more years of
prior health care coverage undergoing hip dual-energy x-ray absorptiometry measurements
(1996–2013). Incident MOF and incident hip fractures were each studied over 7 years. Cox pro-
portional hazards models were adjusted for FRAX (FRAX adjusted) and then FRAX plus comor-
bidity, falls, osteoporosis therapy, or insulin (fully adjusted). FRAX calibration was assessed com-
paring observed vs predicted probabilities.
Results:Therewere49 098womenwithoutand8840womenwithdiabetes (31.4%10yduration;
20.1%5–10 y; 23.7%5 y; 24.8%newonset). In FRAX-adjustedanalyses, only duration longer than
10 yearswas associatedwith a higher risk forMOF (hazard ratio [HR] 1.47, 95%confidence interval
[CI] 1.30–1.66), and this was similar in the fully adjusted models (HR 1.34, 95% CI 1.17–1.54). In
contrast, a higher risk for hip fracture was seen for all durations in a dose-dependent fashion (eg,
FRAX adjusted HR 2.10, 95% CI 1.71–2.59 for duration10 y vs HR 1.32, 95% CI 1.03–1.69 for new
onset). FRAX significantly underestimated the MOF risk (calibration ratio 1.24, 95% CI 1.08–1.39)
andhip fracture risk (1.93, 95%CI1.50–2.35) in thosewithadiabetesduration longer than10years.
Conclusion: Diabetes is a FRAX-independent risk factor for MOF only in women with a long du-
ration of diabetes, but diabetes increases hip fracture risk, regardless of duration. Those with
diabetes longer than 10 years are at particularly high risk of fracture, and this elevated risk is
currently underestimated by FRAX. (J Clin Endocrinol Metab 101: 4489–4496, 2016)
Osteoporosis and type 2 diabetes are both commonchronic diseases that are increasing in prevalence
and share some risk factors such as older age, current
smoking, and exposure to glucocorticoids. Furthermore,
each condition alone increases the risk of fracture, with
type 2 diabetes a bone mineral density (BMD)-indepen-
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dent and fracture risk assessment (FRAX) tool -indepen-
dent risk factor for major osteoporotic fractures (MOF)
and hip fractures (1–3). The reasons that type 2 diabetes
increases the risk of fracture are complex and multifacto-
rial and include skeletal (eg, compromised bone strength
or bone quality, suppressed bone turnover, increased cor-
tical porosity) and nonskeletal factors (eg, increased risk
of injurious falls related to hypoglycemia, obesity, de-
creased visual acuity, and impaired mobility and balance)
(1, 2). All of the putative mechanisms for the associations
between type 2 diabetes and fracture require time to ac-
crue, and a better understanding of the time course be-
tween a diagnosis of diabetes and the risk of fracture is of
clinical value in stratifying the risk of fracture for a given
patient with type 2 diabetes.
Prior studies of different designs among different pop-
ulations and from different time periods have consistently
demonstrated that type 2 diabetes increases the risk of
MOF by about 20%–30% and the risk of hip fracture by
70%–80% (4). There has been, however, much less con-
sistency when trying to examine the duration of type 2
diabetes as a risk factor for osteoporotic fractures, with
studies demonstrating no associationwith duration (5, 6),
increased risk only with long duration of diabetes (7–10),
increased risk with even a short duration of diabetes (11,
12), and even a reduction in the risk of fracture with new-
onset diabetes (13). Larger studies with longer follow-up
and more consistent definitions of diabetes and osteopo-
rosis risk are needed to bring clarity to this topic.
Therefore, we undertook the present analysis in a large
population-based sample of women with and without
type 2 diabetes undergoing dual-energy x-ray absorpti-
ometry (DXA) for clinical indications. We hypothesized
that the duration of diabetes might be more important
than its mere presence or absence and that a longer dura-
tion of diabetes would be positively associated with an
increased risk of incident fracture in a dose-dependent
fashion. Furthermore, given that FRAX (with or without
BMD) already tends to underestimate the risk of fracture
in patients with type 2 diabetes (2, 3), we hypothesized
that any potential miscalibrationwould result in clinically
important underestimation of fracture risk, particularly in
those with the longest duration of diabetes.
Materials and Methods
Subjects and setting
Using a registry containing all clinical DXA results for Mani-
toba,Canada,we identifiedallwomenaged40yearsandolderwith
at least10yearsofhealthcarecoveragebeforeundergoing their first
(baseline) DXA in the years 1996–2013. In the Province of Man-
itoba, Canada, health services are provided to nearly all residents
througha singlepublichealth care system(14,15).DXAtestinghas
been managed as an integrated program since 1997, and this pro-
gram maintains a database of all DXA results that can be linked
withotherpopulation-baseddatabases throughananonymousper-
sonal identifier (16). The DXA database has completeness and ac-
curacy in excess of 99% and has been described in detail (16–18).
This study was approved by the University of Manitoba Health
Research Ethics Board and data access granted by the Manitoba
Health Information Privacy Committee.
Diabetes diagnosis and duration of disease
Women were first categorized according to the presence or
absence of diabetes using a validated algorithm for identifying
individuals with diabetes in population-based health services
data (15). Using data sources since 1987, diabetes was ascer-
tained from the presence of at least two physician billing claims
for diabetes within 2 years (coded using International Classifi-
cation of Diseases, ninth revision, Clinical Modification [ICD-
9-CM]) or at least one hospitalization with a diabetes diagnosis
(coded using the ICD-9-CM prior to 2004 and International
Classification of Diseases, 10th revision, Canada thereafter)
(15). Then we defined our independent variable of interest,
namely the duration of diabetes, based on the earliest applicable
diagnosis code for diabetes. We classified the duration of dia-
betes asnewonset (ie, notpresent at the timeofbaselineDXAtest
but diagnosed within the subsequent 5 y) vs short duration (less
than 5 y prior to DXA) vs intermediate duration (5–10 y prior to
DXA) vs long duration (10 y or more prior to DXA). Because of
the relatively long asymptomatic period associated with type 2
diabetes, changes in definitions and screening, and the observa-
tion that at least one-third of prevalent diabetes is undiagnosed,
we included new-onset diabetes as a separate category rather
than altogether exclude them or include them in the no-diabetes
category. Given the age of the cohort, subjects in this analysis
were presumed to have type 2 diabetes. As a sensitivity analysis,
we reran our analyses after excluding those with a long duration
of diabetes treated with only insulin because this subgroup was
most likely to have type 1 diabetes.
Incident fractures
The main study outcome was incident fracture that occurred
after the baseline DXA test through the observation period end-
ingMarch 31, 2013. Fractures were ascertained through a com-
bination of hospital discharge abstracts and physician billing
claims because this method allows complete capture of any frac-
tures that require treatment irrespective of hospital admission (3,
13, 16–18). Longitudinal health service records were assessed
for the presence of hip, clinical vertebral, forearm, and humerus
fracture codes (collectively designated as MOF) that were not
also associatedwith the presence of trauma codes (3, 13, 16–18).
Hip fractures and forearm fractures were required to have a
site-specific fracture reduction, fixation, or casting code to en-
hance specificity for an acute fracture event. To minimize po-
tential misclassification of prior incident fractures, we required
that there be no hospitalization or physician visit(s) with the
same fracture type in the 6months preceding an incident fracture
diagnosis.
DXA measurements
Proximal femur DXA scans were performed and analyzed by
technicians according to the manufacturer’s guidelines using
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pencil beam (Lunar DPX; GE Lunar) if the measurement was
taken before the year 2000 or fan beam (Lunar Prodigy; GE
Lunar) if the measurement was taken after the year 2000. These
densitometers have been cross-calibrated and demonstrated no
clinically important differences across scanners (eg, within 0.1
SD at the femoral neck) and have shown stable long-term per-
formance (eg, coefficient of variation0.5%) and good in vivo
precision (eg, coefficient of variation of 1.1% for the total hip)
(16–18). Femoral neck T-scores (number of SDs above or below
youngadultmeanBMD)were calculatedbasedon referencedata
for US white females from the National Health and Nutrition
Examination Survey III survey (19).
Potential confounders and other measurements
Ten-year probability of MOF risk and hip fracture risk was
calculated using the World Health Organization FRAX tool,
Canadian version (FRAX Desktop Multi-Patient Entry, version
3.7). The Canadian FRAX tool was calibrated using nationwide
hip fracture data, and its predictions agreed closely with ob-
served fracture risk (17). Weight and height were obtained by
self-report at the time of the DXA examination before the year
2000; thereafter height was assessed with a wall-mounted sta-
diometer and weight was assessed without shoes using a stan-
dard floor scale. Bodymass index (BMI [in kilograms per square
meter])was calculated asweight (in kilograms) divided by height
(in meters) squared. Prior fracture, other FRAX input variables,
and falls requiring hospitalization were assessed using hospital
discharge abstracts and physician billing claims as previously
described (3, 13, 16–18). We defined prior fragility fracture as
any nontraumatic MOF that occurred before the baseline DXA
test using records back to 1987 and used both hospital discharge
abstracts andphysicianbilling claims to capture any fracture that
required treatment whether or not the patient was hospitalized.
Prolonged oral corticosteroid use (90 d dispensed in the 1 y
prior to DXA), as well as any use of prescription osteoporosis
therapy (ie, bisphosphonates, calcitonin, systemic estrogenprod-
ucts, raloxifene, teriparatide) or any oral antidiabetic agents or
insulin in the 1 year prior to baseline DXA test, was obtained
from the provincial pharmacy system. Lastly, to define burden of
comorbidity in the1yearprior to theirbaselineDXAtest for each
subject, we used the Johns Hopkins Adjusted Clinical Group
(ACG) Case-Mix System (version 9) (20, 21). Aggregated diag-
nosis groups (ADGs) represent 32 comorbidity clusters of every
ICD-9-CMdiagnostic codes (20, 21). The number of ADGswas
categorized as less than three (reference group) vs three to five vs
six or more (22).
Statistical analysis
Sociodemographic and clinical characteristics of subjects
with andwithout type 2 diabetes at the time of the baselineDXA
test were described using means and SDs for continuous vari-
ables and frequencies and percentages for categorical variables;
between-group comparisons were conducted using appropriate
statistical tests (eg, 2 tests of independence for categorical vari-
ables). Cumulative incidence of fractures, MOF, and hip frac-
ture, stratified by the presence and duration of diabetes, were
plotted. Then multivariable Cox proportional hazards regres-
sion models were used to test the independent association be-
tween a diagnosis of type 2 diabetes and incident fractures. After
this, we examined the independent association between the du-
ration of diabetes (no diabetes [reference] vs new onset diabetes
vs 5 y duration vs 5–10 y duration vs 10 y duration) and
incident fracture. The model was first adjusted for FRAX scores
computed with femoral neck BMD (log transformed due to a
skewed distribution), hereafter referred to as FRAX adjusted.
Then another model was fit to the data that adjusted for FRAX
scores in addition to burden of comorbidity, hospitalized falls,
prescription osteoporosis treatment, and insulin therapy, here-
after referred to as fully adjusted. The proportional hazards as-
sumptionwas confirmed for eachmodel by testing scaled Schoe-
nfeld residuals vs time, and no violations were detected.
Lastly, we examined the calibration of FRAX computedwith
femoral neck BMD according to different durations of diabetes.
The magnitude of potential miscalibration of FRAX was evalu-
ated by calculating ratios for the observed 10-year incident frac-
ture probability to the expected 10-year fracture probability pre-
dicted by FRAX across each strata of diabetes duration. These
ratios explicitly considered the effect of competing mortality,
which is a component of the FRAXmethodology (23). A priori,
we considered observed fracture rates within 10%of FRAXpre-
dicted rates (ie, an observed to expected calibration ratio any-
wherebetween0.90and1.10) to represent goodcalibration (18).
All statistical analyses were performed with Statistica (version
10.0; StatSoft Inc).
Results
The final study cohort included 8840 women with type 2
diabetes and 49 098 women without diabetes. Women
with diabetes were significantly older and heavier with a
greater burden of comorbidity and more prior falls than
women without diabetes (Table 1). Women with diabetes
were also significantly more likely to have had a prior
fracture, and had higher predicted risk of MOF and hip
fractures, than women without diabetes (Table 1). Over
more than 420 000 person-years of follow-up (mean 7 y
per subject), womenwith diabeteswere significantlymore
likely to suffer an incident MOF than women without
diabetes (814 [9.2% or 14.3 per 1000 person-years] vs
4211 [8.6% or 11.5 per 1000 person-years]; FRAX-ad-
justed hazard ratio [HR] 1.19, 95% [CI] 1.10–1.28, P
.001; fully adjusted HR 1.11, 95% CI 1.03–1.21, P 
.007) and significantly more likely to suffer a hip fracture
thanwomenwithout diabetes (279 [3.2%or 4.9 per 1000
person-years] vs 1109 [2.3% or 3.0 per 1000 person-
years]; FRAX adjusted HR 1.66, 95% CI 1.45–1.89, P
.001; fully adjusted HR 1.56, 95% CI 1.36–1.79, P 
.001). Unlike these osteoporotic fractures, incident ankle
fractureswere not associatedwith the presence of diabetes
(P  .2; Table 1).
Duration of diabetes and incident fractures
Most diagnoses of diabetes preceded DXA testing (n
2776 [31.4%]10 y duration; n 1776 [20.1%] 5–10 y;
n  2098 [23.7%] 5 y duration) with a minority of
diabetes being diagnosed after DXA testing (n  2190
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[24.8%]newonset). Ifwe consideredany subjectwhoever
used insulin but never used an oral antidiabetes agent to
represent type1diabetes, only207of8840 (2.3%)women
with diabetes in our population met this definition, sup-
porting our assumption that our cohort contained pre-
dominantly type 2 diabetes.
Table 2 provides selected baseline characteristics ac-
cording to the duration of diabetes. Compared with those
without diabetes, therewas a statistically significant (P for
linear trend.001) gradient in age, BMI, prior fractures,
and FRAX scores (but not femoral neck bone density)
according to the duration of diabetes (Table 2). A similar
linear gradient in observed rates of incident fracture was
seen according to the duration of diabetes for both MOF
and hip fracture, with a greatest risk of both types of frac-
turesobserved in thosewithmore than10yearsofdiabetes
duration (Table 3).
Multivariable analyses of diabetes duration
With respect to MOF, in FRAX-adjusted analyses, only
diabetes present for a duration longer than 10 years was
independently associatedwith incident fracture, and this as-
sociation remained statistically significant in the fully ad-
justed model (adjusted HR 1.34, 95% CI 1.17–1.54, P 
.001; Table 4). Treatment with insulin was not associated
with MOF (P  .5), and excluding the 207 women with
possible type1diabetesdidnotaffect either themagnitudeor
statistical significance of these findings (data not shown).
With respect to hip fracture, however, any duration of
diabetes was independently associated with an increased
Table 1. Characteristics and Outcomes Stratified According to the Presence or Absence of Diabetes
Diabetes
(n  8840), %
No Diabetes
(n  49 098), %
P Value for
Difference
Characteristics
Age, y 67.1  10.4 63.8  11.1 .0001
BMI, kg/m2 30.3  6.4 26.5  5.1 .0001
Height, cm 159.2  6.5 160.5  6.6 .0001
Weight, kg 76.9  17.2 68.3  13.9 .0001
Prior fracture 1462 (16.5) 7045 (14.3) .0001
Insulin use 832 (9.4) 0 (0) .0001
Osteoporosis treatment 1103 (12.5) 8054 (16.4) .0001
Fracture probability (FRAX MOF with BMD) 12.7  8.7 11.3  8.6 .0001
Fracture probability (FRAX hip with BMD) 2.8  4.6 2.6  4.5 .0001
Femoral neck T-score 1.3  1.1 1.4  1 .0001
Femoral neck Z-score 0.3  1 0,0  0.9 .0001
Femoral neck osteoporosis (T-score 2.5) 974 (11) 6136 (12.5) .0001
Hospitalization for a fall in the last 3 y 428 (4.8) 1610 (3.3) .0001
ADG score 5.6  2.8 4.6  2.6 .0001
Observation time, y 6.5  3.9 7.5  4.2 .0001
Outcomes
Incident hip fractures 279 (3.2) 1109 (2.3) .0001
Incident vertebral fractures 200 (2.3) 945 (1.9) .04
Incident humerus fractures 201 (2.3) 844 (1.7) .0001
Incident forearm fractures 248 (2.8) 1793 (3.7) .0001
Incident MOF fractures 814 (9.2) 4211 (8.6) .05
Incident ankle fractures 153 (1.7) 751 (1.5) .20
Deaths 1666 (18.8) 5454 (11.1) .0001
Table 2. Selected Baseline Characteristics Stratified According to the Presence and Duration of Diabetes
No Diabetes
(n  49 098)
New-Onset
Diabetes
(n  2190)
Duration, <5 y
(n  2098)
Duration, 5–10 y
(n  1776)
Duration, >10 y
(n  2776)
Characteristics, mean (SD)
Age, y 63.8  11.1 65.6  10.7 66.5  10.3 67.9  9.9 68.4  10.4
Body mass index, kg/m2 26.5  5.1 30.4  6.2 30.5  6.4 30.4  6.4 30.0  6.4
Prior fracture, % 14.3  0.3 14.5  0.4 16.0  0.4 15.9  0.4 19.0  0.4
Fracture probability (FRAX MOF
with BMD)
10.9  8.0 11.1  8.0 11.2  7.8 11.7  8.2 12.3  7.9
Fracture probability (FRAX hip
with BMD)
2.6  4.5 2.6  4.6 2.6  4.4 2.9  5.2 3.1  4.5
Femoral neck T-score 1.4  1.0 1.2  1.0 1.2  1.1 1.2  1.0 1.4  1.1
Femoral neck Z-score 0.0  0.9 0.3  0.9 0.3  1.0 0.4  1.0 0.2  1.0
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risk of incident fracture (Table 4). A dose-response gra-
dient was present with diabetes duration longer than 10
years associated with the greatest risk of hip fracture in
both the FRAX-adjustedmodels (adjustedHR 2.10, 95%
CI 1.71–2.59, P  .001) and fully adjusted models (ad-
justed HR 1.94, 95% CI 1.54–2.44, P  .001; see Table
4). Treatment with insulin was not associated with hip
fracture (P .7) and excluding207womenwithpresump-
tive type 1 diabetes did not materially affect either the
magnitudeor statistical significanceof these findings (data
not shown).
FRAX calibration and diabetes duration
FRAXwaswell calibrated forMOFprediction inwomen
without diabetes (ie, desirable range for the calibration ratio
0.90–1.10). With respect to MOF in women with diabetes,
FRAX was well calibrated in fully adjusted models except
when diabetes durationwas longer than 10 years (Figure 1).
In those with a long duration of diabetes, the observed to
expected calibration ratio was 1.24 (95% CI 1.08–1.39),
representing a statistically significant and clinically impor-
tant underestimation of MOF risk (Table 5).
FRAXcalibration for hip fracture predictionwas again
within the desirable range in women without diabetes.
FRAX was not well calibrated in women with diabetes of
any duration (Figure 1). Irrespective of statistical signifi-
cance, the observed to expected calibration ratios ex-
ceeded in magnitude the 1.10 threshold across all dura-
tions of diabetes and statistically significantly exceeded
1.90 in those with the longest duration of diabetes (1.93,
95% CI 1.50–2.35; see Table 5). This represents a clini-
cally important and substantial underestimationof the hip
fracture risk in those with diabetes, particularly in those
with the longest durations of diabetes.
Discussion
In a large cohort of more than 50 000 women undergoing
DXA testing for clinical indications, we confirmed that
type 2 diabetes is a FRAX-independent risk factor for
MOF and hip fractures and demonstrated that the dura-
tionofdiabetes is important in termsofunderstandingand
quantifying this increased risk. Indeed, at least 10 years of
a diagnosis with diabetes needed to be present before
women were at a significantly increased risk of MOF,
whereas the risk of hip fracture was increased even before
the diagnosis of diabetes. That said, the risk of hip fracture
increasedwithdurationof diabetes, such thatwomenwith
10 years ormore of diabetes had almost a doubling in their
hip fracture risk when compared with women without
diabetes, even after adjusting for FRAX with BMD, co-
morbidity, falls, osteoporosis treatment, and insulin ther-
apy.Whereas FRAX is known to underestimate the risk of
Table 3. Rates per 1000 Person-Years (95% Confidence Intervals) of Major Osteoporotic Fracture, Hip Fracture,
and Death According to the Presence and Duration of Diabetes
n
Major Osteoporotic
Fractures Hip Fractures Deaths
No diabetes 49 098 11.4 (10.5–12.4) 3.0 (2.5–3.5) 14.8 (13.8–15.9)
Diabetes 8840 14.3 (11.8–16.7) 4.9 (3.4–6.3) 29.2 (25.7–32.7)
Diabetes duration
New onset 2190 11.9 (7.4–16.4) 3.9 (1.3–6.5) 22.4 (16.2–28.6)
5 y 2098 13.3 (8.4–18.2) 4.5 (1.7–7.4) 27.5 (20.5–34.5)
5–10 y 1776 13.9 (8.5–19.4) 4.8 (1.6–8) 29.3 (21.4–37.1)
10 y 2776 18.0 (13.1–23.0) 6.4 (3.5–9.4) 38.3 (31.2–45.5)
Table 4. FRAX-Adjusted and Fully Adjusteda Associations With Incident Fractures According to the Duration of
Diabetesb
Major Osteoporotic Fractures Hip Fractures
n
FRAX-Adjusted
HR (95% CI)
Fully Adjusted
HR (95% CI)
FRAX-Adjusted
HR (95% CI)
Fully Adjusted
HR (95% CI)
No diabetes 49 098 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
New onset 2190 1.02 (0.89–1.17) 0.99 (0.86–1.14) 1.32 (1.03–1.69) 1.30 (1.01–1.65)
5 y 2098 1.13 (0.98–1.32) 1.07 (0.92–1.25) 1.59 (1.23–2.06) 1.54 (1.19–1.99)
5–10 y 1776 1.16 (0.99–1.37) 1.10 (0.93–1.29) 1.61 (1.21–2.13) 1.55 (1.17–2.06)
10 y 2776 1.47 (1.30–1.66) 1.34 (1.17–1.54) 2.10 (1.71–2.59) 1.94 (1.54–2.44)
a Fully adjusted models included FRAX scores (computed with BMD), burden of comorbidity, falls, prescription osteoporosis treatments, and insulin
therapy.
b Statistically significant (P  .05) HRs in bold.
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fractures in women with type 2 diabetes (2, 3), we dem-
onstrated that it is most severely miscalibrated for both
MOF and hip fractures in those with 10 years or longer of
duration of diabetes.
The findings from theprior literature are inconsistent and
difficult to synthesize, likely because different studies have
included very different sample sizes, examined different geo-
graphic populations over different eras, been restricted to
certain fracture types, or ascertained diabetes diagnoses and
durations using variable methods (5–13). Strotmeyer et al
(Health, Aging, BodyComposition Study [5]) andAhmed et
al (Tromso Study [6]) reported no association between any
type of fracture and duration of diabetes. Schwartz et al
(Study of Osteoporotic Fractures [7]) reported all fracture
types increasedwith long (14 y) duration of diabetes com-
pared with shorter durations of diabetes, although this
reachedstatistical significanceonlyforhipfracture (riskratio
[RR] 2.40 [95% CI 1.55–3.71] compared with no diabetes
Figure 1. FRAX calibration plots: observed vs predicted 10-year probabilities and their associated observed to predicted ratios for major
osteoporotic fractures and hip fractures. A priori, we considered observed to predicted ratios between 0.9 and 1.10 to represent good calibration
and values outside these bounds to represent clinically important miscalibration. *, Values of P  .05 represents a statistically significant
miscalibration.
Table 5. Effect of Diabetes Duration on FRAX Calibration According to Observed Versus Predicted 10-Year
Fracture Probability Ratioa
Major Osteoporotic Fractures Hip Fractures
n
Observed vs
Predicted Ratio
95% Confidence
Intervals
Observed vs
Predicted Ratio
95% Confidence
Intervals
Diabetes
No Diabetes 49 098 0.98 0.95–1.01 1.08 1.01–1.15
New onset 2190 0.94 0.80–1.07 1.18 0.85–1.51
5 y 2098 1.07 0.90–1.24 1.79 1.30–2.27
5–10 y 1776 1.13 0.94–1.33 1.46 0.98–1.95
10 y 2776 1.24 1.08–1.39 1.93 1.50–2.35
a Statistically significant (P  .05) ratios in bold.
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and RR 1.46 [95%CI 0.98–2.17] compared with short du-
ration of diabetes). This association with a longer duration
has been confirmed by Forsen et al (Nord-TrondelagHealth
Study [8] ), Ivers et al (Blue Mountains Eye Study [9]), and
Melton et al (Rochester Minnesota cohort [10]), who ob-
served significantly an increased risk of fracture only after 5
years, 10 years, and 10 years of duration of diabetes, respec-
tively. Janghorbanietal (Nurses’HealthStudy[11])reported
an increased risk of hip fracture with any diabetes duration,
although the risk was greatest with a long (11 y) duration
of disease, findings nearly identical with that of Nicodemus
and Folsom (Iowa Women’s Health Study [12]).
Finally, in a population-based case-control study
drawn from the same province as the current study, Leslie
et al (13) showed that a longer (5 y) duration of diabetes
was associated with an increased risk of MOF (RR 1.15,
95% CI 0.86–0.95) and hip fractures (RR 1.40, 95% CI
1.28–1.53). These investigators also found a biphasic as-
sociation with diabetes wherein subjects with new-onset
diabetes during follow-up had a 9% reduced risk ofMOF
and a 17% reduced risk of hip fracture (13). This latter
finding has not been replicated by others and is not con-
sistentwithour currentworkor the findingsofNicodemus
and Folsom (12) in which new-onset diabetes was very
similar in fracture risk to established diabetes of less than
5 years’ duration. This protective benefit of a new diag-
nosis of diabetes is also difficult to interpret, given that
type 2 diabetes often has a 5- to 10-year asymptomatic
latency period and that at the time of diagnosis most pa-
tients alreadyhave somediabetes-related complicationsor
comorbidities (24).
Although the literature is not straightforward to inter-
pret, we believe that the totality of evidence indicates that
type 2diabetes increases the risk ofMOFandhip fractures
and that the longer the duration of disease, the greater the
risk of fracture, particularly a decade after the diagnosis.
Whatdoes this imply for fracture riskassessment?For type
1 diabetes, the current consensus is to consider it a sec-
ondary osteoporosis FRAX input and assumes that some
(although not all) of the increased risk relates to reduced
BMDin this population (2, 25). For type2diabetes, FRAX
computed with BMD is miscalibrated and underestimates
the risk, especially for hip fracture and especially for those
with a long duration of disease. Although more work
needs to be done and our findings need to be replicated,
type 2 diabetes of 10 years’ duration should be considered
a red flag for greater attention to osteoporosis, perhaps
thought of as a previous fracture equivalent at the bedside
(24) in the way that a long duration of diabetes is some-
times considereda coronaryheart disease equivalentwhen
undertaking cardiac risk stratification (26).
This study has several strengths, including its large and
population-based sample size, its long look-back and fol-
low-up periods, its capture of both BMI and BMD, and its
use of previously validated methods to capture both ex-
posure (diabetes) andoutcome (fractures).Nevertheless, it
also has several important limitations. First, we cannot
distinguish type 1 from type 2 diabetes, and thismay be an
important pathophysiological distinction. Given the age
of cohort entry (40y) and the look-backperiod (10y), only
a very small proportion (maximum 2.3%) of those with
diabetes in our study potentially had type 1 diabetes. Fur-
thermore, sensitivity analyses in which we excluded all
207 subjects who ever used insulin and never used oral
antidiabetes agents did not materially affect any of our
findings, confirming that this was a study dominated by
those with type 2 diabetes as was intended.
Second, diagnoses of diabetes were based on adminis-
trative data, and we did not have measurements of fasting
glucose or glycated hemoglobin, and thus, we could not
examine the role of impaired fasting glucose or prediabe-
tes on the one hand nor guarantee that our control group
did not have undiagnosed diabetes on the other hand.
Third, we did not have any measures of glycemic control
or, related to this, measures of bone strength or quality as
influencedbyglycemic control. Fourth,wehadnodetailed
information on smoking; physical activity; falls not re-
quiring hospitalization or mediators of falling such as hy-
poglycemia; ormeasures of diabetic complications such as
neuropathy, myopathy, retinopathy, or nephropathy; or
chronic kidney disease. Fifth, we did not examine time-
updated covariates such as changes in BMI, BMD, or
FRAX clinical risk factors or the addition of new medi-
cations during follow-up but rather examined only cova-
riates at the time of the baseline DXA test. Sixth, our frac-
ture data were based on claims data and procedure codes,
and although validated and specific (27, 28), we did not
have information with respect to asymptomatic or non-
clinical vertebral fractures. Lastly, our findings may lack
generalizability because the population was drawn from
one province in Canada and the subjects were predomi-
nantly white, and we examined only women.
In conclusion, confirming a diagnosis of type 2 diabetes
significantly increases the risk of hip fracture, and once a
woman has had type 2 diabetes for a decade (all else being
equal), she has more than a 30% increased risk of MOF
and more than a 90% increased risk of hip fracture when
comparedwith awomanwithout diabetes. These substan-
tially elevated risks as they relate to duration of disease
have not been captured using conventional fracture risk
assessment tools such as FRAX.
doi: 10.1210/jc.2016-2569 press.endocrine.org/journal/jcem 4495
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